Keros Therapeutics, Inc. KROS · Stock Open Keros Therapeutics, Inc. in new tab
Keros Therapeutics, Inc. Analysis (KROS)
Is Keros Therapeutics, Inc. a good investment? Keros Therapeutics, Inc. (KROS) is currently trading at 11.48 USD. Market analysts have a consensus price target of 19.83 USD. This suggests a potential upside from current levels.
In terms of valuation, the stock trades at a P/E ratio of 4.61. This relatively low multiple may signal that Keros Therapeutics, Inc. is undervalued compared to historical market norms.
Earnings Schedule: Keros Therapeutics, Inc. is expected to release its next earnings report on Nov. 4, 2026. The market consensus estimate for Forward EPS is -6.62.
Investor FAQ
Does Keros Therapeutics, Inc. pay a dividend?
No, it does not currently pay a dividend.
What asset class is Keros Therapeutics, Inc.?
Keros Therapeutics, Inc. is classified as a Stock. You can compare it against its peer in the "Related Symbols" list.
When is the next earnings date?
The next earnings date is projected to be Nov. 4, 2026. The company currently has a trailing EPS of -3.22.
Company Profile
Keros Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics to treat patients with disorders linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. It develops rinvatercept, which acts as a ligand trap and inhibits the biological effects of myostatin and activin A in Phase 1 clinical trials for Duchenne Muscular Dystrophy and Amyotrophic Lateral Sclerosis; and elritercept to target TGF-ß signaling pathways to address diseases that arise from ineffective hematopoiesis in Phase 3 clinical trials for Myelodysplastic Syndromes and Phase 2 clinical trials for Myelofibrosis. The company has collaboration and license agreements with Hansoh (Shanghai) Healthtech Co., Ltd. to develop, manufacture, and commercialize elritercept and licensed products containing elritercept; and Takeda Pharmaceuticals U.S.A., Inc. to develop, manufacture, and commercialize elritercept and certain derivative compounds. Keros Therapeutics, Inc. was incorporated in 2015 and is headquartered in Lexington, Massachusetts.
Community Discussion